| Hyperprolactinaemia during treatment with paliperidone. | |
| | |
MedLine Citation:
|
PMID: 20429680 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The aim of this paper is to highlight the association between antipsychotic medication, in this instance paliperidone, and hyperprolactinaemia, and discuss the impact of this adverse effect on patient management. METHOD: Four patients with paliperidone-induced hyperprolactinaemia are described with a brief review of the literature. RESULTS: Four female patients aged between 20 and 50 years developed hyperprolactinaemia 3 weeks to 4 months after commencement of treatment with paliperidone. The levels were significantly raised above the normal upper limit of 500 mIU/L, ranging between 1500 and 3996 mIU/L, and returned to within the normal range after cessation of the medication (82-381 mIU/L). Two of the patients were asymptomatic despite significant elevation of prolactin; two experienced galactorrhoea, a distressing adverse effect. Subsequent management was significantly affected. CONCLUSIONS: Routine standardized monitoring of prolactin levels may guide treatment choice, avoiding potential disruption to the therapeutic relationship, enhancing compliance with future medication and preventing negative treatment outcomes. Detailed education should accompany the monitoring process and include discussion of the risks of associated adverse effects of antipsychotic medications versus the benefit of significant symptom relief. |
| | |
Authors:
|
Michaela Skopek; Puthenpurackal Manoj |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists Volume: 18 ISSN: 1440-1665 ISO Abbreviation: Australas Psychiatry Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-20 Completed Date: 2010-08-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9613603 Medline TA: Australas Psychiatry Country: England |
Other Details:
|
Languages: eng Pagination: 261-3 Citation Subset: IM |
Affiliation:
|
Gosford Hospital, Northern Sydney Central Coast Area Health Service, NSW, Australia. michaelaskopek@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antipsychotic Agents / adverse effects*, therapeutic use Dibenzothiazepines / therapeutic use Dose-Response Relationship, Drug Drug Administration Schedule Drug Monitoring Female Galactorrhea / blood, chemically induced Humans Hyperprolactinemia / blood, chemically induced* Isoxazoles / adverse effects*, therapeutic use Middle Aged Patient Compliance / psychology Piperazines / therapeutic use Prolactin / blood Psychotic Disorders / blood, drug therapy*, psychology Pyrimidines / adverse effects*, therapeutic use Quinolones / therapeutic use Recurrence Schizophrenia, Paranoid / blood, drug therapy*, psychology Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents; 0/Dibenzothiazepines; 0/Isoxazoles; 0/Piperazines; 0/Pyrimidines; 0/Quinolones; 0/quetiapine; 129722-12-9/aripiprazole; 144598-75-4/9-hydroxy-risperidone; 9002-62-4/Prolactin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A primer of clinical psychiatry.
Next Document: How the philosophy of Merleau-Ponty can help us understand the gulf between clinical experience and ...